SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J.W.L. Keogh, A. Patel, R.D. MacLeod, J. Masters, Perceived barriers and facilitators to physical activity in men with prostate cancer: possible influence of androgen deprivation therapy, European Journal of Cancer Care, 2014, 23, 2
  2. 2
    Daroh Lim, Mina Ha, Inmyung Song, Trends in the Leading Causes of Death in Korea, 1983-2012, Journal of Korean Medical Science, 2014, 29, 12, 1597

    CrossRef

  3. 3
    Peter D. Baade, Danny R. Youlden, Susanna M. Cramb, Jeff Dunn, Robert A. Gardiner, Epidemiology of prostate cancer in the Asia-Pacific region, Prostate International, 2013, 1, 2, 47

    CrossRef

  4. 4
    F Fontes, M Severo, C Castro, S Lourenço, S Gomes, F Botelho, C La Vecchia, N Lunet, Model-based patterns in prostate cancer mortality worldwide, British Journal of Cancer, 2013, 108, 11, 2354

    CrossRef

  5. 5
    Masaru Ishida, Shiho Kashiyama, Naoyoshi Koike, Rei Ohara, Nobuhiro Tsukamoto, Yosuke Nakajima, Palliative cyberknife therapy successfully controlled lower extremity lymphedema caused by pelvic lymph node metastases after radiation therapy for localized prostate cancer: a case report, Palliative Care Research, 2013, 8, 2, 560

    CrossRef

  6. 6
    Justin W. L. Keogh, Asmita Patel, Roderick D. MacLeod, Jonathan Masters, Perceptions of physically active men with prostate cancer on the role of physical activity in maintaining their quality of life: possible influence of androgen deprivation therapy, Psycho-Oncology, 2013, 22, 12
  7. 7
    R Ogawa, A Morii, A Watanabe, Z-G Cui, G Kagiya, N Doi, Q L Zhao, L B Feril, An artificially constructed radiation-responsive promoter is activated by doxorubicin, Cancer Gene Therapy, 2012, 19, 5, 345

    CrossRef

  8. 8
    Justin W.L. Keogh, Roderick D. MacLeod, Body Composition, Physical Fitness, Functional Performance, Quality of Life, and Fatigue Benefits of Exercise for Prostate Cancer Patients: A Systematic Review, Journal of Pain and Symptom Management, 2012, 43, 1, 96

    CrossRef

  9. 9
    Debasish Sundi, Byong Chang Jeong, Seung Bae Lee, Misop Han, Optimizing the Management of High-Risk, Localized Prostate Cancer, Korean Journal of Urology, 2012, 53, 12, 815

    CrossRef

  10. 10
    Alex Faulkner, Resisting the screening imperative: patienthood, populations and politics in prostate cancer detection technologies for the UK, Sociology of Health & Illness, 2012, 34, 2
  11. 11
    Leander Van Neste, James G Herman, Gaëtan Otto, Joseph W Bigley, Jonathan I Epstein, Wim Van Criekinge, The Epigenetic promise for prostate cancer diagnosis, The Prostate, 2012, 72, 11
  12. 12
    Robert Abouassaly, Ian M. Thompson, Elizabeth A. Platz, Eric A. Klein, Campbell-Walsh Urology, 2012,

    CrossRef

  13. 13
    Sheng Fei Oon, Stephen R. Pennington, John M. Fitzpatrick, R. William G. Watson, Biomarker research in prostate cancer—towards utility, not futility, Nature Reviews Urology, 2011, 8, 3, 131

    CrossRef

  14. 14
    Sheng F. Oon, R. William Watson, John J. O’Leary, John M. Fitzpatrick, Epstein criteria for insignificant prostate cancer, BJU International, 2011, 108, 4
  15. 15
    Zhenhua HE, Ye ZHANG, Satish K. MEHTA, Duane L. PIERSON, Honglu WU, Larry H. ROHDE, Expression Profile of Apoptosis Related Genes and Radio-sensitivity of Prostate Cancer Cells, Journal of Radiation Research, 2011, 52, 6, 743

    CrossRef

  16. 16
    Robert Abouassaly, Sophie D. Fossa, Aleksander Giwercman, Christian Kollmannsberger, Robert J. Motzer, Hans-Joachim Schmoll, Cora N. Sternberg, Sequelae of Treatment in Long-term Survivors of Testis Cancer, European Urology, 2011, 60, 3, 516

    CrossRef

  17. 17
    Kyung Won Seo, Young Kee Kwon, Byung Hoon Kim, Chun Il Kim, Hyuk Soo Chang, Mi Sun Choe, Choal Hee Park, Correlation between Claudins Expression and Prognostic Factors in Prostate Cancer, Korean Journal of Urology, 2010, 51, 4, 239

    CrossRef

  18. 18
    A-E. Carsin, F. J. Drummond, A. Black, P. J. van Leeuwen, L. Sharp, L. J. Murray, D. Connolly, L. Egevad, M. Boniol, P. Autier, H. Comber, A. Gavin, Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland, Cancer Causes & Control, 2010, 21, 9, 1523

    CrossRef

  19. 19
    P. Vineis, A. Schatzkin, J. D. Potter, Models of carcinogenesis: an overview, Carcinogenesis, 2010, 31, 10, 1703

    CrossRef

  20. 20
    F. Bray, J. Lortet-Tieulent, J. Ferlay, D. Forman, A. Auvinen, Prostate cancer incidence and mortality trends in 37 European countries: An overview, European Journal of Cancer, 2010, 46, 17, 3040

    CrossRef

  21. 21
    R. Kvåle, B. Møller, A. Angelsen, O. Dahl, S.D. Fosså, O.J. Halvorsen, L. Hoem, A. Solberg, R. Wahlqvist, F. Bray, Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007, Cancer Epidemiology, 2010, 34, 4, 359

    CrossRef

  22. 22
    Xiaoye Zhu, Monique J Roobol, Fritz H Schröder, Screening for prostate cancer: have we resolved the controversy?, Current Opinion in Supportive and Palliative Care, 2010, 4, 3, 121

    CrossRef

  23. 23
    Peter D. Baade, Danny R. Youlden, Lauren J. Krnjacki, International epidemiology of prostate cancer: Geographical distribution and secular trends, Molecular Nutrition & Food Research, 2009, 53, 2
  24. 24
    G. Draisma, R. Etzioni, A. Tsodikov, A. Mariotto, E. Wever, R. Gulati, E. Feuer, H. de Koning, Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context, JNCI Journal of the National Cancer Institute, 2009, 101, 6, 374

    CrossRef

  25. You have free access to this content25
    Alison L. Moore, Polyxeni Dimitropoulou, Athene Lane, Philip H. Powell, David C. Greenberg, Clement H. Brown, Jenny L. Donovan, Freddie C. Hamdy, Richard M. Martin, David E. Neal, Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer, BJU International, 2009, 104, 11
  26. 26
    K. Kraywinkel, M. Lehnert, A. Semjonow, H.-W. Hense, Aktuelle Daten zur Epidemiologie des Prostatakarzinoms, Der Urologe, 2008, 47, 7, 853

    CrossRef

  27. 27
    Gregory S. Merrick, Kent E. Wallner, Robert W. Galbreath, Wayne M. Butler, Sarah G. Brammer, Zachariah A. Allen, Jonathan H. Lief, Edward Adamovich, Biochemical and Functional Outcomes Following Brachytherapy With or Without Supplemental Therapies in Men ≤50 Years of Age With Clinically Organ-Confined Prostate Cancer, American Journal of Clinical Oncology, 2008, 31, 6, 539

    CrossRef

  28. 28
    A. Cayuela, S. Rodríguez-Domínguez, E. Vigil Martín, R. Barrero Candau, Cambios recientes en la mortalidad por cáncer de próstata en España: estudio de tendencias en el período 1991-2005, Actas Urológicas Españolas, 2008, 32, 2, 184

    CrossRef

  29. 29
    Janet L. Colli, Christopher L. Amling, Exploring causes for declining prostate cancer mortality rates in the United States, Urologic Oncology: Seminars and Original Investigations, 2008, 26, 6, 627

    CrossRef

  30. 30
    Vincent Misraï, Morgan Rouprêt, Emmanuel Chartier-Kastler, Eva Comperat, Raphaële Renard-Penna, Alain Haertig, Marc-Olivier Bitker, François Richard, Pierre Conort, Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer, World Journal of Urology, 2008, 26, 5, 481

    CrossRef

  31. 31
    André N. Vis, Stijn Roemeling, Ardine M.J. Reedijk, Suzie J. Otto, Fritz H. Schröder, Overall Survival in the Intervention Arm of a Randomized Controlled Screening Trial for Prostate Cancer Compared with a Clinically Diagnosed Cohort, European Urology, 2008, 53, 1, 91

    CrossRef

  32. 32
    Fritz H. Schröder, Progress in Understanding Androgen-Independent Prostate Cancer (AIPC): A Review of Potential Endocrine-Mediated Mechanisms, European Urology, 2008, 53, 6, 1129

    CrossRef

  33. 33
    Jan-Erik Damber, Gunnar Aus, Prostate cancer, The Lancet, 2008, 371, 9625, 1710

    CrossRef

  34. 34
    Simon M Collin, Richard M Martin, Chris Metcalfe, David Gunnell, Peter C Albertsen, David Neal, Freddie Hamdy, Peter Stephens, J Athene Lane, Rollo Moore, Jenny Donovan, Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study, The Lancet Oncology, 2008, 9, 5, 445

    CrossRef

  35. 35
    Hiroyuki Takechi, Kazuto Ito, Takumi Yamamoto, Mai Miyakubo, Masaru Ohi, Kazuhiro Suzuki, Prostate-Specific Antigen Kinetics in Screen-Detected Prostate Cancer in Japan, Urology, 2008, 72, 5, 1111

    CrossRef

  36. 36
    Christine Bouchardy, Gerald Fioretta, Elisabetta Rapiti, Helena Maria Verkooijen, Charles Henry Rapin, France Schmidlin, Raymond Miralbell, Roberto Zanetti, Recent trends in prostate cancer mortality show a continuous decrease in several countries, International Journal of Cancer, 2008, 123, 2
  37. 37
    Richard J. Bryant, Freddie C. Hamdy, Screening for Prostate Cancer: An Update, European Urology, 2008, 53, 1, 37

    CrossRef

  38. 38
    T. Kinsey, A. Jemal, J. Liff, E. Ward, M. Thun, Secular Trends in Mortality From Common Cancers in the United States by Educational Attainment, 1993-2001, JNCI Journal of the National Cancer Institute, 2008, 100, 14, 1003

    CrossRef

  39. 39
    Sabina Hussain, David Gunnell, Jenny Donovan, Sean McPhail, Freddie Hamdy, David Neal, Peter Albertsen, Julia Verne, Peter Stephens, Caroline Trotter, Richard M. Martin, Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975–2004, BJU International, 2008, 101, 5
  40. 40
    Jan Adolfsson, Watchful waiting and active surveillance: the current position, BJU International, 2008, 102, 1
  41. 41
    Peter Albertsen, Treatment Methods for Early and Advanced Prostate Cancer, 2008,

    CrossRef

  42. 42
    David K. Espey, Xiao-Cheng Wu, Judith Swan, Charles Wiggins, Melissa A. Jim, Elizabeth Ward, Phyllis A. Wingo, Holly L. Howe, Lynn A. G. Ries, Barry A. Miller, Ahmedin Jemal, Faruque Ahmed, Nathaniel Cobb, Judith S. Kaur, Brenda K. Edwards, Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives, Cancer, 2007, 110, 10
  43. 43
    Moustapha Dieye, Jacqueline Veronique-Baudin, Cyprian Draganescu, Herv?? Azaloux, Cancer incidence in Martinique: a model of epidemiological transition, European Journal of Cancer Prevention, 2007, 16, 2, 95

    CrossRef

  44. 44
    R. M. Martin, Commentary: Prostate cancer is omnipresent, but should we screen for it?, International Journal of Epidemiology, 2007, 36, 2, 278

    CrossRef

  45. 45
    Margaret A. Parsons, Kathleen D. Askland, Determinants of prostate cancer stage in northern New England: USA Franco-American contextual effects, Social Science & Medicine, 2007, 65, 10, 2018

    CrossRef

  46. 46
    Barbara K. Dunn, Leslie G. Ford, Hormonal interventions to prevent hormonal cancers: breast and prostate cancers, European Journal of Cancer Prevention, 2007, 16, 3, 232

    CrossRef

  47. 47
    Gunnar Aus, Svante Bergdahl, Pär Lodding, Hans Lilja, Jonas Hugosson, Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial, European Urology, 2007, 51, 3, 659

    CrossRef

  48. 48
    A. Cayuela Domínguez, E. Vigil Martín, S. Rodríguez-Domínguez, R. Medina López, M. Conde Sánchez, Tendencias divergentes en la mortalidad por cáncer de próstata en la Comunidad Autónoma de Andalucía (1975-2004), Actas Urológicas Españolas, 2007, 31, 2, 92

    CrossRef

  49. 49
    Suzie J. Otto, Monique J. Roobol, Case Control Studies in Evaluating Prostate Cancer Screening: An Overview, EAU-EBU Update Series, 2006, 4, 6, 219

    CrossRef

  50. 50
    Claude C. Schulman, Laurent Boccon-Gibod, Introduction, European Urology Supplements, 2006, 5, 3, 359

    CrossRef

  51. 51
    Morgan Rouprêt, Gaëlle Fromont, Marc-Olivier Bitker, Bernard Gattegno, Guy Vallancien, Olivier Cussenot, Outcome after radical prostatectomy in young men with or without a family history of prostate cancer, Urology, 2006, 67, 5, 1028

    CrossRef

  52. 52
    Stefano Ciatto, Ginetta Gervasi, Giuseppe Gorini, Claudio Lombardi, Marco Zappa, Emanuele Crocetti, Prostate cancer specific mortality in the Florence screening pilot study cohort 1992–1993, European Journal of Cancer, 2006, 42, 12, 1858

    CrossRef

  53. 53
    J Constantinou, M R Feneley, PSA testing: an evolving relationship with prostate cancer screening, Prostate Cancer and Prostatic Diseases, 2006, 9, 1, 6

    CrossRef

  54. 54
    Nikolaus Becker, Hans-Peter Altenburg, Christa Stegmaier, Hartwig Ziegler, Report on trends of incidence (1970–2002) of and mortality (1952–2002) from cancer in Germany, Journal of Cancer Research and Clinical Oncology, 2006, 133, 1, 23

    CrossRef

  55. 55
    Tatjana Pekmezovic, Peter Baade, Trends and patterns in prostate cancer mortality in Belgrade, Serbia: a join-point analysis, European Journal of Cancer Prevention, 2006, 15, 1, 51

    CrossRef

  56. 56
    James A. Hanley, Analysis of Mortality Data From Cancer Screening Studies, Epidemiology, 2005, 16, 6, 786

    CrossRef

  57. 57
    L. Di Matteo, R. Di Matteo, Does testing for prostate-specific antigen contribute to declining prostate cancer mortality?, The European Journal of Health Economics, 2005, 6, 4, 298

    CrossRef

  58. 58
    JANE MELIA, Part 1: The burden of prostate cancer, its natural history, information on the outcome of screening and estimates of ad hoc screening with particular reference to England and Wales, BJU International, 2005, 95,
  59. 59
    Shandra S. Wilson, Prostate cancer screening, Comprehensive Therapy, 2005, 31, 2, 119

    CrossRef

  60. 60
    Gunnar Aus, David Robinson, Johan Rosell, Gabriel Sandblom, Eberhard Varenhorst, Survival in prostate carcinoma—Outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up, Cancer, 2005, 103, 5
  61. 61
    Mark Elwood, A misleading paper on prostate cancer screening, The Prostate, 2004, 61, 4
  62. 62
    J.-E. Damber, Decreasing mortality rates for prostate cancer: possible role of hormonal therapy?, BJU International, 2004, 93, 6
  63. 63
    Freddie Bray, Wendy Atkin, International cancer patterns in men: geographical and temporal variations in cancer risk and the role of gender, The Journal of Men's Health & Gender, 2004, 1, 1, 38

    CrossRef

  64. 64
    Fabio Levi, Franca Lucchini, Eva Negri, Peter Boyle, Carlo La Vecchia, Leveling of prostate cancer mortality in Western Europe, The Prostate, 2004, 60, 1
  65. 65
    Otis W Brawley, Prostate cancer screening: Clinical applications and challenges☆, Urologic Oncology: Seminars and Original Investigations, 2004, 22, 4, 353

    CrossRef

  66. 66
    Shandra S. Wilson, E. David Crawford, Screening for Prostate Cancer, Clinical Prostate Cancer, 2004, 3, 1, 21

    CrossRef

  67. 67
    Shandra S. Wilson, E.David Crawford, Screening for prostate cancer: current recommendations, Urologic Clinics of North America, 2004, 31, 2, 219

    CrossRef

  68. 68
    Suzie J Otto, Harry J de Koning, Update on screening and early detection of prostate cancer, Current Opinion in Urology, 2004, 14, 3, 151

    CrossRef

  69. 69
    P.S. Pinheiro, J.E. Tyczyński, F. Bray, J. Amado, E. Matos, D.M. Parkin, Cancer incidence and mortality in Portugal, European Journal of Cancer, 2003, 39, 17, 2507

    CrossRef

  70. 70
    Suzie J. Otto, Ingrid W. van der Cruijsen, Michael K. Liem, Ida J. Korfage, Jan J. Lous, Fritz H. Schröder, Harry J. de Koning, Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer, International Journal of Cancer, 2003, 105, 3
  71. 71
    Francesco La Rosa, Fabrizio Stracci, Liliana Minelli, Vito Mastrandrea, Epidemiology of prostate cancer in the Umbria region of Italy: evidence of opportunistic screening effects, Urology, 2003, 62, 6, 1040

    CrossRef

  72. 72
    G. Draisma, R. Boer, S. J. Otto, I. W. van der Cruijsen, R. A. M. Damhuis, F. H. Schroder, H. J. de Koning, Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer, JNCI Journal of the National Cancer Institute, 2003, 95, 12, 868

    CrossRef

  73. 73
    Phyllis A. Wingo, Cheryll J. Cardinez, Sarah H. Landis, Robert T. Greenlee, Lynn A. G. Ries, Robert N. Anderson, Michael J. Thun, Long-term trends in cancer mortality in the United States, 1930–1998, Cancer, 2003, 97, S12
  74. 74
    Andrew R. Moot, Adrian Polglase, Graham G. Giles, O. Margaret Garson, Vicky Thursfield, David Gunter, Men with colorectal cancer are predisposed to prostate cancer, ANZ Journal of Surgery, 2003, 73, 5
  75. 75
    G. Draisma, H.J. De Koning, MISCAN: estimating lead-time and over-detection by simulation, BJU International, 2003, 92,
  76. 76
    Andrew Bayley, Mary K. Gospodarowicz, Radiotherapy for T3 prostate cancer, Current Urology Reports, 2003, 4, 3, 205

    CrossRef

  77. 77
    S.E. Oliver, J.L. Donovan, T.J. Peters, S. Frankel, F.C. Hamdy, D.E. Neal, Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion, BJU International, 2003, 91, 4
  78. 78
    Stephen Frankel, George Davey Smith, Jenny Donovan, David Neal, Screening for prostate cancer, The Lancet, 2003, 361, 9363, 1122

    CrossRef

  79. 79
    Fritz H Schröder, Screening for prostate cancer, Urologic Clinics of North America, 2003, 30, 2, 239

    CrossRef

  80. 80
    P. Boyle, Screening for prostate cancer: have you had your cholesterol measured?, BJU International, 2003, 92, 3
  81. 81
    A. Auvinen, J. Hugosson, The rationale for the ERSPC trial: will it improve the knowledge base on prostate cancer screening?, BJU International, 2003, 92,
  82. 82
    Edward Messing, The timing of hormone therapy for men with asymptomatic advanced prostate cancer, Urologic Oncology: Seminars and Original Investigations, 2003, 21, 4, 245

    CrossRef

  83. 83
    Kenneth C. Chu, Robert E. Tarone, Harold P. Freeman, Trends in prostate cancer mortality among black men and white men in the United States, Cancer, 2003, 97, 6
  84. 84
    James A Talcott, What patients should be told before agreeing to a blood test that could change their lives, Urology, 2003, 61, 1, 7

    CrossRef

  85. 85
    Ihor C. Sawczuk, Ahmad Shabsigh, Prostate Cancer, 2003,

    CrossRef

  86. 86
    Brenda K. Edwards, Holly L. Howe, Lynn A. G. Ries, Michael J. Thun, Harry M. Rosenberg, Rosemary Yancik, Phyllis A. Wingo, Ahmedin Jemal, Ellen G. Feigal, Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden, Cancer, 2002, 94, 10
  87. 87
    John Anderson, Does PSA Testing Influence the Natural History of Prostate Cancer?, European Urology Supplements, 2002, 1, 5, 3

    CrossRef

  88. 88
    Ye Zhang, Jiang Yu, Emmanual Unni, Tsang C. Shao, Bicheng Nan, Thiti Snabboon, Susan Kasper, Francesca Andriani, Larry Denner, Marco Marcelli, Monogene and Polygene Therapy for the Treatment of Experimental Prostate Cancers by Use of Apoptotic GenesbaxandbadDriven by the Prostate-Specific Promoter ARR2PB, Human Gene Therapy, 2002, 13, 17, 2051

    CrossRef

  89. 89
    Anssi Auvinen, Freda E. Alexander, Harry J. de Koning, Anthony B. Miller, Should we start population screening for prostate cancer? Randomised trials are still needed, International Journal of Cancer, 2002, 97, 3
  90. 90
    Marc Arbyn, Helena Geys, Trend of cervical cancer mortality in Belgium (1954–1994): Tentative solution for the certification problem of unspecified uterine cancer, International Journal of Cancer, 2002, 102, 6
  91. 91
    Fritz H Schröder, Harry J de Koning, The Norwegian decision on screening for prostate cancer: a response, The Lancet Oncology, 2001, 2, 12, 746

    CrossRef

  92. 92
    Alex Faulkner, Resisting the Screening Imperative: Patienthood, Populations and Politics in Prostate Cancer Detection Technologies for the UK,